Health Care · Services-Medical Laboratories

GH Guardant Health, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1576280214 filings
Russell 2000

GH at a glance

Guardant Health, Inc. (GH, SEC CIK 1576280) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Guardant Health, Inc. (GH) reported revenue of $982.0 million (up 32.9% from FY2024) and a net loss of $416.3 million. Diluted EPS was -$3.32.
  • As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Guardant Health, Inc. (GH) shares worth $9.8 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Monroe Terilyn J. on November 18, 2026 of 500 shares at $140.64 per share.
  • In the last 90 days, GH insiders reported 0 open-market purchases ($0) and 17 open-market sales ($4.0M) on Form 4, a net sale of $4.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$982.0M
+32.9% vs prior year
Insiders · 90 days
0 buys · 17 sells
Net −$4.0M
13F holders
35 funds
$9.8B · −1 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 2.03 · Item 3.02 · Item 8.01 · Item 1.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Precision oncology company providing liquid biopsy and blood-based tests for cancer detection, treatment selection, and monitoring across all disease stages
  • New emphasis: Expanded Guardant Reveal test for late-stage therapy response monitoring; Shield test granted FDA Breakthrough Device status for multi-cancer detection
  • Strategic shift: Migration of key tests (Guardant360 Liquid, Reveal) to proprietary Smart Platform leveraging multiomic data and AI for enhanced sensitivity and insights
  • Quantitative highlight: Global expansion includes launch of Guardant360 CDx testing at Policlinico Gemelli in Italy (Dec 2025) and reimbursement approval in Japan (July 2023)
  • Noteworthy fact: Shield blood test is first FDA-approved and Medicare-covered primary colorectal cancer screening blood test, now included in NCCN screening guidelines

Risk Factors

  • Medicare reimbursement 10%+ of revenue in 2025, 2024, 2023; risk from CMS regulation changes hindering direct billing
  • Geopolitical and economic instability, including wars, terrorism, pandemics, may disrupt business and affect operating results
  • Limited laboratory capacity and unautomated processes constrain scaling; facility expansion and equipment procurement delays possible
  • Competitor Roche-owned Foundation Medicine, Exact Sciences, and others increasing M&A and development efforts in liquid biopsy and genomic profiling
  • Revenue concentration: Top 5 biopharmaceutical customers contributed 11% of total revenue in 2025, risking material financial impact if lost

Management Discussion & Analysis

  • Revenue $982.0M in 2025 vs $739.0M in 2024, up $243M or 32.9% YoY
  • Net loss improved to $416.3M in 2025 from $436.4M in 2024, margin not explicitly stated
  • Best segment: Oncology tests for clinical customers, supported by expanded Medicare coverage and FDA approvals
  • Worst segment: Not explicitly stated; overall net losses indicate ongoing high operating expenses
  • Cash & equivalents $1.3B as of Dec 31, 2025; capital allocation details on buybacks/dividends not disclosed
  • Increased R&D spending on new product innovation and large clinical studies (e.g., Shield post-approval SOLAR study)
  • Management outlook highlights focus on international expansion, payer coverage improvements, and reimbursement risks

AI summary of the GH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $361.0M, up 36% YoY from $265.2M
  • Operating loss $132.8M vs $99.0M YoY, operating margin (36.8%) vs (37.3%)
  • Best segment Screening: $67.6M, up 180% YoY; worst growth Biopharma and data: $59.0M, up 8%
  • Cash, equivalents and restricted cash $1.1B; nine-month operating cash outflow $147.1M vs $158.4M
  • Outlook: additional operating losses expected; liquidity sufficient for more than 12 months, reimbursement variability remains a headwind

Risk Factors

  • New cybersecurity risk triggered by unauthorized portal access, with certain patient records potentially accessed
  • AI-enabled attacks increasing speed, scale and sophistication of exploitation
  • Regulatory exposure from compromised patient data, including investigations, enforcement actions and penalties
  • Operational disruption risk across testing, reporting, billing and reimbursement systems
  • Third-party service-provider vulnerabilities potentially compromising Guardant information systems

AI summary of the GH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 points investors to Item 1.01 for details on Guardant Health’s newly created financial obligation
  • The obligation relates to the company’s indenture and notes, potentially affecting leverage, interest expense and future liquidity

Item 3.02: Unregistered Sales of Equity Securities

  • Convertible Notes sold privately under Section 4(a)(2) and Rule 144A, limiting initial availability to institutional investors
  • Maximum 3,553,385 common shares issuable upon conversion, creating potential shareholder dilution

Item 8.01: Other Events

  • Proposed offering announced November 11, 2026, signaling planned capital raising by Guardant Health
  • Offering pricing announced November 12, 2026, with terms in Exhibit 99.2

Item EX-99.2: Item EX-99.2

  • $500M 0% convertible notes due May 15, 2032, with potential $50M upsizing option
  • Net proceeds approximately $489.3M, rising to $538.3M if fully upsized

Item EX-99.1: Item EX-99.1

  • Proposed $500.0M convertible senior notes due May 15, 2032, plus $50.0M overallotment option
  • Refinancing strategy: proceeds may repurchase a portion of 0% convertible notes due 2027

Item 1.01: Entry into a Material Definitive Agreement

  • $550M 0% convertible notes due 2032, expanding long-term financing without regular cash interest expense
  • $501.7M used to repurchase $395.2M of 2027 notes, reducing near-term refinancing risk
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Guardant Health announced financial results for the quarter ended September 30, 2026
  • Detailed revenue, earnings, cash flow and guidance information appears in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $361.0M, up 36%, led by Oncology revenue $231.3M and Screening revenue $67.6M, up 180%
  • Test volumes accelerated: Oncology 117,000, up 58%, and Shield 83,000, up 246% year over year
Filed Nov 3, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Retention signal: founders and Co-CEOs Helmy Eltoukhy and AmirAli Talasaz each received 465,413 target PSUs
  • 100% performance-based awards tied to relative TSR versus S&P 500 over three-year and five-year periods

AI summaries of GH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for GH

Don't miss the next GH filing

  • Alerts as it files. A push when GH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut GH, by share count.
  • Ask anything. An AI agent that reads every GH filing and answers with sources.

GH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Monroe Terilyn J.SellNov 18, 2026$140.64
Monroe Terilyn J.SellNov 18, 2026$141.79
Monroe Terilyn J.SellNov 18, 2026$142.83
Monroe Terilyn J.SellNov 18, 2026$143.64
Monroe Terilyn J.SellNov 18, 2026$144.58
Hidalgo Medina ManuelMNov 17, 2026-
Hidalgo Medina ManuelMNov 17, 2026-
Tariq MusaSellNov 16, 2026$149.56

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$739.0M$982.0M
Operating Income--$443.6M-$437.2M
Net Income-$479.4M-$436.4M-$416.3M
Op. Margin--60.0%-44.5%
Net Margin--59.0%-42.4%
Balance Sheet
Total Assets-$1.5B$2.0B
Equity$158.7M-$139.6M-$99.3M
ROE-302.1%312.5%419.2%
Per Share
EPS$-4.28$-3.56$-3.32
Cash Flow
Operating CF--$239.9M-$184.8M
CapEx$20.5M$35.1M$48.3M

Source: XBRL data in Guardant Health, Inc. (GH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate GH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
GH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202635$9.76B
Q2 202636$9.27B
Q1 202636$6.00B
Q4 202533$5.61B
Q3 202532$3.21B
Q2 202533$2.74B
Q1 202530$1.48B
Q4 202423$856.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 258 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

GH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 18, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
8-KNov 16, 2026Analysis-
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 12, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
8-KNov 3, 2026Analysis-
8-KNov 3, 2026Analysis-
4Oct 22, 2026--
4Oct 19, 2026--
4Oct 19, 2026--
4Oct 15, 2026--
4Oct 13, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--

Related Health Care companies

All Health Care →

GH SEC filings: frequently asked questions

Are GH insiders buying or selling?

In the last 90 days, Guardant Health, Inc. (GH) officers, directors and 10% owners reported no open-market purchases and 17 open-market sales worth $4.0 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold GH stock?

As of September 30, 2026, the largest Guardant Health, Inc. (GH) holders among the 13F filers tracked by SignalX were BlackRock ($1.4 billion), Vanguard Capital Management LLC ($1.0 billion), T. Rowe Price Group ($1.0 billion), Vanguard Portfolio Management LLC ($951.6 million), Franklin Resources ($571.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was GH's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Guardant Health, Inc. (GH) reported revenue of $982.0 million (up 32.9% from FY2024) and a net loss of $416.3 million. Diluted EPS was -$3.32. The figures come from the XBRL data in the 10-K.

What are the main risks in GH's latest 10-K?

In the 10-K filed February 19, 2026, Guardant Health, Inc. (GH) flagged: Medicare reimbursement 10%+ of revenue in 2025, 2024, 2023; risk from CMS regulation changes hindering direct billing. Geopolitical and economic instability, including wars, terrorism, pandemics, may disrupt business and affect operating results. (AI summary of the Risk Factors section.)

What did GH report in its latest 8-K?

Guardant Health, Inc. (GH) filed an 8-K on November 16, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events) and Item 1.01 (Entry into a Material Definitive Agreement). Item 2.03 points investors to Item 1.01 for details on Guardant Health’s newly created financial obligation.

What are the latest GH SEC filings?

Guardant Health, Inc. (GH) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 19, 2026.

What is GH's SEC CIK number?

Guardant Health, Inc. (GH)'s SEC Central Index Key (CIK) is 1576280. EDGAR lists every GH filing under that number.

Ask anything about GH

The research agent reads GH's filings, financials, insider trades and 13F holders, then answers with sources.